Please login to the form below

Not currently logged in
Email:
Password:

Acorda

This page shows the latest Acorda news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

There were two other positive opinions on new medicines at the CHMP meeting last week, with the panel backing Acorda Therapeutics’ inhaled Inbrija (levodopa) for the treatment of symptoms of ‘off’

Latest news

  • Biotech leaders jump into US free speech debate Biotech leaders jump into US free speech debate

    Alnylam chief executive John Maraganore, Decibel Therapeutics’ CEO Steve Holtzman, Acorda CEO Ron Cohen and Jeremy Levin of Ovid Therapeutics are the main signatories to the letter published In Nature, but

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201.

  • Acorda acquires Biotie to expand in Parkinson's disease Acorda acquires Biotie to expand in Parkinson's disease

    Strikes $363m deal for Finnish firm. Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates. ... The deal will also give Acorda four phase III programmes that -

  • Multiplying options for MS

    Acorda and Biogen Idec's Ampyra (fampridine sustained-release), a potassium channel antagonist that has been shown to restore conduction in demyelinated axons in patients with MS, was approved in the

  • A competitive edge

    Philippines. Dalfampridine . Ampyra (Acorda Therapeutics). Multiple sclerosis. USA, Puerto Rico. Desirudin .

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    410. Biotie Oy/ Acorda. Acquisition company. CNS portfolio includes tozadenant for Parkinson's in p2b .

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    675. Acorda Therapeutics/Civitas Therapeutics. Company acquisition. Includes CVT 301 in P3 for Parkinson's as well as pulmonary delivery technology.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    601. Civitas / Acorda. Company acquisition. CVT-301 - Levodopa dry powder inhaler. Phase IIb for treatment of Parkinsons pulmonary delivery technology.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Acquisition of complementary and competitor companies. The acquisition of Civitas for $525m provides Acorda with a product for Parkinson's disease in phase IIb that complements its CNS portfolio.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Dr Catherine Strader joins Acorda Therapeutics’ board Dr Catherine Strader joins Acorda Therapeutics’ board

    Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader. ... Dr Ron Cohen, Acorda's president and chief executive officer, said: “Catherine brings decades of experience as both a drug developer and

  • Acorda Therapeutics appoints chief medical officer Acorda Therapeutics appoints chief medical officer

    New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer. ... Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs.

  • Acorda appoints new CFO Acorda appoints new CFO

    Michael Rodgers replaces David Lawrence who becomes chief business officer. Acorda has reshuffled its senior business leadership, with Michael Rodgers appointed chief financial officer replacing David Lawrence who becomes chief business ... I'm excited

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics